The global insulin delivery devices market is on a steady growth trajectory, projected to reach USD 52.7 billion by 2030 from USD 35.3 billion in 2025, growing at a CAGR of 8.3% during the forecast period. As diabetes continues to emerge as one of the world’s most pressing healthcare challenges, demand for innovative, patient-friendly insulin delivery solutions is accelerating across both developed and emerging economies.
From traditional insulin syringes to smart insulin pens and advanced insulin pumps, the market is undergoing a major transformation. Healthcare providers, patients, and manufacturers are increasingly focused on improving treatment adherence, enhancing convenience, and enabling better glucose management through technology-driven solutions.
Download PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092
Why Insulin Delivery Devices Are Becoming Essential in Modern Diabetes Care
One of the primary drivers fueling market expansion is the growing prevalence of type 1 and type 2 diabetes worldwide. Aging populations, sedentary lifestyles, rising obesity rates, and unhealthy dietary habits are contributing to a significant increase in diabetes diagnoses, creating sustained demand for insulin therapies and delivery systems.
Traditional insulin administration methods often present challenges related to dosing accuracy, convenience, and patient compliance. Modern insulin delivery devices help overcome these barriers by offering easier administration, improved precision, and enhanced comfort.
Insulin pens have gained widespread acceptance because of their portability, ease of use, and dosing accuracy. Meanwhile, insulin pumps are becoming increasingly popular among patients seeking continuous insulin delivery and better glycemic control. The growing adoption of automated insulin delivery systems and connected diabetes management platforms is further accelerating market growth.
Healthcare systems worldwide are also increasing investments in diabetes treatment and management programs. This rise in healthcare spending is creating favorable conditions for the adoption of advanced insulin delivery technologies, particularly in regions experiencing rapid growth in diabetic populations.
Innovation and Strategic Investments Are Reshaping the Competitive Landscape
The insulin delivery devices industry is witnessing substantial innovation as manufacturers focus on developing smarter, more connected, and user-friendly solutions.
A major milestone occurred in January 2025, when Novo Nordisk launched Awiqli (insulin icodec injection) in Japan using a prefilled FlexTouch pen. The product represents an important advancement in insulin therapy by supporting once-weekly insulin administration, potentially reducing treatment burden for patients.
In May 2024, Novo Nordisk received approval from the European Medicines Agency (EMA) for Awiqli (insulin icodec), including its delivery through the company’s FlexTouch prefilled pen platform. This approval marked a significant step toward improving treatment convenience and adherence.
The company further strengthened its manufacturing capabilities in December 2024 through the acquisition of three production facilities following Novo Holdings’ acquisition of Catalent. This strategic move supports Novo Nordisk’s long-term objective of expanding access to diabetes and obesity treatments globally.
Meanwhile, Embecta Corp. has been actively advancing innovation through partnerships and technology integration. In May 2023, the company partnered with Tidepool to develop an automated insulin delivery (AID) system specifically designed for individuals with type 2 diabetes. The collaboration combines Embecta’s expertise in delivery devices with Tidepool’s advanced diabetes management software capabilities.
Request for Sample Pages: – https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092
These developments highlight a broader industry trend: insulin delivery is no longer focused solely on administering medication. Companies are increasingly competing through digital integration, connected devices, automation, and personalized diabetes management solutions.
Companies Leading the Insulin Delivery Devices Revolution
Several multinational healthcare and medical technology companies continue to shape the future of insulin delivery through innovation, product development, and strategic expansion.
Embecta Corp.
Embecta has emerged as one of the world’s leading providers of insulin delivery solutions following its spin-off from BD (Becton, Dickinson and Company) in 2022. The company operates in more than 100 countries and maintains a dominant position in insulin injection technologies.
Its manufacturing scale is substantial, producing approximately 6 billion pen needles and 1.5 billion insulin syringes annually. The company’s strong Medicare Part D payer relationships in the United States have further strengthened its market presence.
Through its partnership with Tidepool and continued investments in automated insulin delivery technologies, Embecta is positioning itself as a key innovator in next-generation diabetes management.
Novo Nordisk A/S
Novo Nordisk remains one of the most influential companies in diabetes care globally. The company offers an extensive portfolio of insulin therapies, GLP-1 products, insulin pens, needles, and digital diabetes management solutions.
Operating in more than 170 markets worldwide, Novo Nordisk has consistently invested in advanced delivery technologies. Products such as the NovoPen 6 and smart insulin solutions demonstrate the company’s commitment to improving patient outcomes through innovation.
The acquisition of BIOCORP Production SA in 2023 further expanded its capabilities in connected drug delivery systems, supporting its vision of integrating insulin devices with digital healthcare platforms.
Medtronic Plc
Medtronic continues to play a critical role in the insulin pump segment. The company is recognized for its advanced diabetes management systems, continuous glucose monitoring integration, and automated insulin delivery technologies.
Its extensive global reach and commitment to research and development have helped establish Medtronic as a leader in technology-driven diabetes care.
Sanofi
Sanofi has maintained a strong position in diabetes treatment through its insulin portfolio and innovative delivery devices. The company’s focus on improving patient convenience and treatment adherence continues to support its growth within the insulin delivery devices market.
Eli Lilly and Company
Eli Lilly remains a major force in diabetes therapeutics and insulin delivery innovation. The company continues to invest in advanced insulin pens and next-generation diabetes solutions designed to enhance patient outcomes and simplify treatment administration.
Market Competition Remains Intense
The insulin delivery devices market remains highly competitive, with the top five companies accounting for approximately 25% to 50% of total market share. Market leadership is determined by factors such as product portfolio breadth, technological innovation, regulatory approvals, geographic reach, and commercialization capabilities.
Embecta, Novo Nordisk, Medtronic, Sanofi, and Eli Lilly collectively represent the industry’s most influential players. Their strong focus on product innovation, strategic collaborations, and global expansion continues to drive market evolution.
At the same time, a large portion of the market—between 50% and 75%—remains controlled by regional and emerging manufacturers. This fragmentation creates significant opportunities for smaller companies to introduce innovative technologies and capture niche market segments.
What’s Next for the Insulin Delivery Devices Market?
The future of the insulin delivery devices market looks highly promising as diabetes prevalence continues to rise globally. Advances in smart insulin pens, connected devices, artificial intelligence, and automated insulin delivery systems are expected to transform how diabetes is managed over the coming decade.
Digital health integration will likely become a key differentiator, with devices increasingly offering features such as dose tracking, real-time monitoring, mobile application connectivity, and personalized treatment recommendations.
As healthcare systems focus on improving patient outcomes while reducing long-term treatment costs, insulin delivery technologies that support self-management and remote monitoring will see increasing adoption.
Ultimately, insulin delivery devices are evolving beyond simple injection tools. They are becoming integral components of comprehensive diabetes management ecosystems. Supported by rising healthcare investments, continuous innovation, and growing patient demand, the market is positioned for sustained growth through 2030 and beyond.
Enquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=107632092